<?xml version="1.0" encoding="UTF-8"?>
<p id="par0045">Baloxavir is a new antiviral medication with a mechanism of action of inhibiting the endonuclease activity of the polymerase acidic (PA) protein, part of the viral RNA polymerase complex required for viral gene transcription [
 <xref rid="bib0050" ref-type="bibr">10</xref>]. A recent study comparing the use of baloxavir to oseltamivir in hospitalized patients with influenza, showed increased resolution of hypoxemia as well as a shorter duration of hypoxia in the baloxavir [
 <xref rid="bib0055" ref-type="bibr">11</xref>]. However, this study did not specify the severity of the disease. Currently, there is an ongoing trial comparing the efficacy of baloxavir and oseltamivir to baloxavir and placebo in patients with severe disease [ClinicalTrials.gov Identifier: NCT02954354]. Our patient was not eligible due prior exposure to oseltamivir and chronic kidney disease.
</p>
